Inside deNOVO Biolabs’ COVID-Era Supply Mission
In 2020, the global life sciences industry faced a supply chain crisis it had never rehearsed for.
COVID-19 didn’t just disrupt commercial operations – it fractured the intricate web of international reagent supply that research laboratories, diagnostic developers, and vaccine programs depend on every day. Shipments were delayed by weeks, then months. Cold-chain integrity became impossible to guarantee across international transit. Global suppliers, overwhelmed and understaffed, prioritised large institutional orders. Smaller and mid-size research programs were left waiting.
For one of India’s leading vaccine development programs, that wait was not an option.
The challenge: A mission-critical Reagent, at scale, during a Pandemic
In mid-2020, deNOVO Biolabs received a request from a major Indian vaccine developer actively working on a COVID-19 vaccine candidate. The team required a specific, high-quality immunology research reagent – a product central to their development and quality validation workflow – in quantities significantly beyond standard commercial supply.
The constraints were severe:
→ International suppliers were either unavailable or had lead times of 3–4 months
→ The reagent required strict quality specifications: defined purity, validated biological activity, and stringent lot-to-lot consistency
→ The development timeline could not accommodate delays
→ Cold-chain management for international shipments was unreliable
The vaccine developer turned to deNOVO Biolabs, a decision grounded in a pre-existing trust relationship and our track record of delivering technically demanding, custom research reagents.
The response: Scale, Speed and Zero Compromise on Quality
Our team at our Bangalore facility immediately began scaling production. The mandate was clear: match the exact technical specifications required, produce at the volumes needed, and deliver on a schedule that the development program could depend on.
What this required in practice:
Accelerated batch production:
Our manufacturing team ran extended production cycles to meet volume requirements without sacrificing QC hold times or release criteria.
Rigorous in-process quality control:
Every batch was subjected to full activity validation, purity assessment, and consistency checks before release. No batch shipped without meeting specification, regardless of timeline pressure.
Coordinated local logistics:
Operating within India meant we could manage cold-chain integrity end-to-end. Deliveries reached the client within 24–48 hours of batch release – a turnaround that no international supplier could have offered at that moment.
Continuous technical liaison:
Our scientific team remained in close contact with the client’s researchers throughout, providing documentation, CoA support, and technical guidance as their program evolved.
The outcome: Delivered at the time of need
deNOVO Biolabs supplied the required reagent across multiple batches throughout the program – maintaining consistency, quality, and schedule adherence through one of the most logistically challenging periods in recent memory.
The vaccine developer’s program progressed. Their supply risk was eliminated. And the experience proved something we now hold as a foundational principle:
India’s critical research and healthcare programs must not depend on imported reagents for mission-critical applications.
The lesson
The COVID supply crisis wasn’t an anomaly. It was a stress test that exposed a systemic vulnerability: the Indian life sciences sector’s over-reliance on international reagent suppliers for products that could – and should – be manufactured domestically.
At deNOVO Biolabs, that experience sharpened our commitment to three things:
- Domestic manufacturing depth: We continue to expand our manufacturing capabilities so that volume surges — whether driven by a public health emergency or a client’s scale-up — can be absorbed without compromising quality or timelines.
- Validated, not just claimed, performance: Every reagent we produce is validated in relevant matrices, not just buffer systems. Our clients need data they can take to regulators, publications, and development decisions.
- Partnership, not just supply: Our team doesn’t just ship a product. We support your assay development, troubleshoot your workflow, and stay available when your program demands answers quickly.
If you are running a research, diagnostic, or biologics development program in India and need a reagent partner who has already been tested under the most demanding conditions imaginable – we are ready!
Our product portfolio includes:
→ Biosimilar PK & Immunogenicity ELISA Kits (DeQuanto™ series)
→ Recombinant Proteins for IVD & Research Applications
→ Custom Monoclonal & Polyclonal Antibody Development
→ Cell-Based Assay & Lateral Flow Assay Development Services
Delivered within 24–48 hours to Tier 1 cities across India. Backed by our Bangalore-based technical team.
📩 Explore our full product catalogue: www.denovobiolabs.com/products
📞 Discuss your requirements: www.denovobiolabs.com/contact-us